Nothing Special   »   [go: up one dir, main page]

MX2024007270A - Proteinas de fusion de citocinas duales que comprenden citocinas de multiples subunidades. - Google Patents

Proteinas de fusion de citocinas duales que comprenden citocinas de multiples subunidades.

Info

Publication number
MX2024007270A
MX2024007270A MX2024007270A MX2024007270A MX2024007270A MX 2024007270 A MX2024007270 A MX 2024007270A MX 2024007270 A MX2024007270 A MX 2024007270A MX 2024007270 A MX2024007270 A MX 2024007270A MX 2024007270 A MX2024007270 A MX 2024007270A
Authority
MX
Mexico
Prior art keywords
cytokines
cytokine fusion
subunit
dual
cytokine
Prior art date
Application number
MX2024007270A
Other languages
English (en)
Inventor
John Mumm
Original Assignee
Deka Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deka Biosciences Inc filed Critical Deka Biosciences Inc
Publication of MX2024007270A publication Critical patent/MX2024007270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La solicitud es concerniente con una composición de proteína de fusión de citocina dual, composición farmacéutica y/o formulación de la misma que comprende las citocinas de múltiples subunidades alfa y beta, tales como IL-12 o IL-27, fusionadas a un sistema de andamiaje de fragmento variable de cadena única y una segunda citocina, en donde la segunda citocina es unida en la región de bisagra del scFv. La solicitud también se refiere a métodos de uso de la composición de proteína de fusión de citocinas duales para tratar cáncer, enfermedades o trastornos inflamatorios y enfermedades o trastornos inmunitarios y mediados por inmunidad.
MX2024007270A 2021-12-13 2022-12-13 Proteinas de fusion de citocinas duales que comprenden citocinas de multiples subunidades. MX2024007270A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163265339P 2021-12-13 2021-12-13
US202263320750P 2022-03-17 2022-03-17
US202263328990P 2022-04-08 2022-04-08
PCT/US2022/081460 WO2023114775A2 (en) 2021-12-13 2022-12-13 Dual cytokine fusion proteins comprising multi-subunit cytokines

Publications (1)

Publication Number Publication Date
MX2024007270A true MX2024007270A (es) 2024-06-26

Family

ID=86773585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007270A MX2024007270A (es) 2021-12-13 2022-12-13 Proteinas de fusion de citocinas duales que comprenden citocinas de multiples subunidades.

Country Status (8)

Country Link
US (1) US20230287075A1 (es)
EP (1) EP4448016A2 (es)
KR (1) KR20240156653A (es)
AU (1) AU2022410872A1 (es)
CA (1) CA3240903A1 (es)
IL (1) IL313525A (es)
MX (1) MX2024007270A (es)
WO (1) WO2023114775A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116322785A (zh) * 2020-07-20 2023-06-23 德卡生物科学公司 包含il-10的双细胞因子融合蛋白

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580485B2 (en) * 2011-07-27 2017-02-28 Philogen S.P.A. IL-12 immunoconjugate
KR102674807B1 (ko) * 2011-12-12 2024-06-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
KR101811050B1 (ko) * 2015-09-02 2017-12-21 경북대학교 산학협력단 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물
WO2019201866A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Fusion protein
KR20210021468A (ko) * 2018-05-14 2021-02-26 웨어울프 세라퓨틱스, 인크. 활성화가능한 사이토카인 폴리펩타이드 및 이의 사용 방법

Also Published As

Publication number Publication date
KR20240156653A (ko) 2024-10-30
CA3240903A1 (en) 2023-06-22
AU2022410872A1 (en) 2024-07-11
IL313525A (en) 2024-08-01
US20230287075A1 (en) 2023-09-14
WO2023114775A2 (en) 2023-06-22
WO2023114775A3 (en) 2023-09-21
EP4448016A2 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
Abdi et al. Free IL-12p40 monomer Is a polyfunctional adaptor for generating novel IL-12–like heterodimers extracellularly
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
MX2024007270A (es) Proteinas de fusion de citocinas duales que comprenden citocinas de multiples subunidades.
WO2020057541A8 (en) Anti-ifnar1 antibodies for treating autoimmune diseases
MX2023000948A (es) Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10).
MX2022009390A (es) Compuestos de unión a il-7r¿¿c.
EP3969120A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF TREATING CANCER IN COMBINATION WITH INTERLEUKIN PROTEIN ANALOGS
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
CR20230507A (es) Anticuerpos anti-il-2r agonistas y métodos de uso
WO2020057540A8 (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
Leonardi et al. New and emerging therapies in psoriasis
PH12020551648A1 (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
Rautenschlein et al. Bioactivities of a tumour necrosis-like factor released by chicken macrophages
BR112023002455A2 (pt) Anticorpos fgfr3 e métodos de uso
BR112023018768A2 (pt) Anticorpos de upar e proteínas de fusão com os mesmos
Morizane et al. “Input/output cytokines” in epidermal keratinocytes and the involvement in inflammatory skin diseases
MX2021001524A (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso.
WO2023115033A3 (en) Dual cytokine fusions comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer
EP4085918A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER, COMPRISING AN IMMUNE CHECKPOINT INHIBITOR AND A FUSION PROTEIN CONSISTING OF IL-2 PROTEIN AND CD80 PROTEIN
WO2022235645A3 (en) Vhh polypeptides that bind to interleukin 6 (il-6), compositions and methods of use thereof
MX2023011929A (es) Anticuerpos anti-c-met y conjugados de anticuerpo-farmaco.
EP4144761A4 (en) RECOMBINANT PROTEIN HAVING FUSED INTERFERON-BETA MUTEIN AND ANTIBODY, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
Zdravkovic et al. Physiology and pathology of cytokine: Commercial production and medical use
WO2022265679A3 (en) FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF